Incidence and Predictors of Tuberculosis Occurrence among Adults on Antiretroviral Therapy at Debre Markos Referral Hospital, Northwest Ethiopia: Retrospective Follow-up Study

Agazhe Aemro
Tseda Health Science college

Abebaw Jember
University of Gondar

Degefaye Zelalem Anlay (degefaye@gmail.com)
University of Gondar

Research article

Keywords: Ethiopia, Incidence, HIV Infection, TB/HIV infection

Posted Date: August 13th, 2019

DOI: https://doi.org/10.21203/rs.2.12735/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published at BMC Infectious Diseases on March 26th, 2020. See the published version at https://doi.org/10.1186/s12879-020-04959-y.
Abstract

Abstract Background: In resource limited settings, Tuberculosis (TB) is the major cause of morbidity and mortality among patients on antiretroviral treatment. Ethiopia is one of the 30 high TB burden countries and it causes burden in healthcare system and challenge the effectiveness of HIV care. This study was to assess incidence and predictors of Tuberculosis among adults on antiretroviral therapy at Debre Markos Referral Hospital, Northwest Ethiopia, 2019. Methods: Institution based retrospective follow up study was conducted among adults on ART newly enrolled from 2014 to 2018 at Debre Markos Referral Hospital. Simple random sampling technique was used to select charts. Data was entered to EPI-INFO version 7.2.2.6 and analyzed using Stata 14.0. Tuberculosis incidence rate was computed and described using frequency tables. Both bivariable and multivariable Cox proportional hazard models was fitted to identify predictors of TB. Results: Out of the 536 charts reviewed, 494 patient records were included in the analysis. A total of 62 patients have developed new TB cases during the follow up period of 1000.22 Person Years (PY); which gives an overall incidence rate of 6.19 cases per 100 PY (95% CI: 4.83 - 7.95). The highest rate was seen within the first year of follow up. TB free survival probability for the total cohort decreased with follow up year. Base line Hemoglobin < 10 g/dl (AHR= 5.25; 95% CI: 2.52 - 10.95), ambulatory/bedridden patients at enrolment (AHR = 2.31; 95% CI: 1.13 - 4.73), having fair or poor ART adherence (AHR = 3.22; 95% CI: 1.64 – 6.31) were increase the risk of tuberculosis whereas taking Isoniazid Preventive Therapy (IPT) (AHR = 0.33; 95% CI: 0.12 - 0.85) were protective factors of TB occurrence. Conclusion: TB Incidence was high among adults on ART especially in the first year of enrollment to ART. Low hemoglobin level, ambulatory or bedridden functional status, non-adherence to ART and IPT usage status were found to be independent predictors. Hence, continuous follow up for ART adherence and provision of IPT has a great importance to reduce the risk of TB. Key words: Ethiopia, Incidence, HIV Infection, TB/HIV infection

Background

Tuberculosis (TB) is the most frequently diagnosed opportunistic infection among peoples living with human immunodeficiency virus (PLHIV). It remains one of the world’s leading causes of ill health and death among PLHIV (1-5). Due to the immunological impairment associated to HIV infection, PLHIV are at higher risk of developing TB (6). According to the 2017 global report, the risk of developing TB was 20 times higher in people living with HIV than in those without HIV (3, 7). Generally, the life time risk of HIV positive individuals to develop TB is 50% and the annual risk is 10% (8).

From 2018 United Nations Program on HIV/AIDS (UNAIDS) global report, in 2017 there were 36.9 million peoples living with HIV. Of this 35.1 million were adults of age 15 year and above and about 940,000 people died from acquired immune deficiency syndrome (AIDS) related illnesses. TB accounts for around one in three AIDS related deaths (1) and from all TB/HIV related death about 84% is accounted in Africa (7).

Antiretroviral therapy has substantial potential to prevent HIV associated tuberculosis. So, in order to control HIV associated tuberculosis epidemic, earlier initiation of antiretroviral therapy may be a key component of global and national strategies (9). Those patients who start ART earlier had a significantly higher rate of survival than those patients who started ART later (2).
The high burden of TB among patients accessing ART services in resource limited settings is a major cause of morbidity and mortality and is associated with nosocomial transmission risk which in turn results in multidrug resistant disease. Even though screening and diagnosis of TB among HIV patients is difficult (10), a newly emerging diagnostic tools, like gene Xpert and sputum culture, show great promise in providing more rapid diagnosis of TB in ART services, which is an essential component of patient care (11).

Ethiopia is among the 30 high TB, HIV and multi drug resistant TB burden countries that accounted an overall annual TB incidence rate of 164 cases per 100,000 populations (8, 12, 13). Similarly, it is also one of the highly affected countries by the TB/HIV co-infection epidemic and associated with special diagnostic and therapeutic challenges resulting in extremely large burden on healthcare systems (14).

In a cohort of adult HIV patients at Zewditu Memorial Hospital, followed from 2005 through 2009, showed that the incidence rate of TB for total follow up period was 3.1 cases per 100 person year (15). Another five year retrospective follow up study conducted at Arbaminich General Hospital, from 2007 – 2013, showed that the incidence rate of TB was 5.36 cases per 100 person year (16). The same study conducted in Afar public health facilities, Ethiopia, between 2010 and 2015 revealed that the overall incidence rate of TB was 8.6 cases per 100 person year (17). Similar five year follow up study conducted at Gondar University Referral Hospital from 2007 to 2012 revealed the overall incidence rate of TB was 7.88 cases per 100 person year with high burden of TB incidence at the first year (18).

Despite progress in care and prevention, the current speed of decline in the epidemiological burden of TB is not fast enough to reach targets set in the Sustainable Development Goals (SDGs). On the other hand, there is a global strategy known as “The End TB Strategy” aiming in reduction of TB incidence rate by 90% at the end of 2035. So, in order to ensure good progress of this strategy the current study has its own implication. Therefore, this study aimed to assess incidence and predictors of TB among adults on ART at Debre markos Referal Hospital.

Methods

Study design, setting and period

An institution based retrospective follow up study was conducted at Debre Markos Referral Hospital which is found in Debre Markos town. Debre Markos town is located in Misrak Gojjam Zone of Amhara Nation Regional State with a latitude and longitude of 10°20′N 37°43′E, and an elevation of 2,446 meters above sea level (19). It is situated 299 km from Addis Ababa, the capital city of Ethiopia, and 265 km from Bahir Dar, capital city of Amhara Nation Regional State (20). Based on the 2007 national census conducted by the Central Statistical Agency (CSA) of Ethiopia, in 2012 Debre Markos has had an estimated population of 262,497, of whom 129,921 were men and 132,576 women (19).

Debre Markos town has one referral hospital, four public health centers and seven private clinics. According to 2015 Debre Markos Referral Hospital human resource administration 3rd quarter report, the hospital was expected to serve for more than five million people in the East and west Gojjam Zone (21). The hospital gives different services in outpatient inpatient departments, of which HIV care service is the one started at 2005.
From the beginning, the hospital has providing ART service for around 6,350 patients who came from different areas and from this 5,839 were adults. Of this, 1264 HIV infected adults were enrolled to ART clinic between Jan 1, 2014 and Dec 31, 2018. There are 4 outpatient units that provide ART service in the hospital with average visit of 36-40 patients to each unit per day (22). From four units two are for adults, one unit for pediatrics and the fourth one is for treatment of OIs. The study was conducted between Jan 1, 2014 and Dec 31, 2018 among adults on ART.

**Inclusion criteria**

All adults aged 15 years and above who were newly started HAART and having at least one follow up at Debre Markose Hospital from Jan 1, 2014 to Dec 31, 2018 were included in this study. Whereas, those adults diagnosed as having TB and unrecorded for TB status at a baseline were excluded. Within this specified period a total of 1264 adult patients were initiated HAART and 1117 fulfill the inclusion criteria, of which 536 participants were selected.

**Sample size and sampling procedure**

Sample size was estimated by using single population proportion formula through EPI INFO statistical package version 7.2.2.6 with the assumption of 95% level of confidence, 2% marginal error, and by taking the incidence of TB 5.36% from previous study (16). With these assumptions the sample size became 487. Considering 10% expected incomplete record the final sample size was 536. Between January 1, 2014 and December 31, 2018 a total of 1264 adult patients were initiated HAART and 1117 fulfill the inclusion criteria, of which 536 participants were selected. The patients’ chart number is taken from the electronic data base of the Hospital and 536 (out of 1117) charts were selected through computer generated random number.

**Operational definition**

Incident TB case in this study is defined as, the occurrence of TB cases after ART initiation which is bacteriologically confirmed (with at least one positive AFB microscopy, Xpert MTB/RIF assay positive, or culture positive) or based on Clinical decision of expert clinician by analyzing the supportive evidences (suggestive of TB) during follow up (23). It is considered to as an events of interest. Patients with the first date of lost, drop out, transfer out, died or completed follow up period before developing tuberculosis were considered as censored. Level of adherence to ART drug in this study is classified as, Good ($\geq$ 95% adherence or missing 1 out of 30 doses or missing 2 out of 60 doses), Fair (85-94% adherence or missing 2 – 4 out of 30 doses or missing 4 – 9 out of 60 doses), Poor (less than 85% or missing $\geq$ 5 doses of 30 doses or $\geq$ 10 dose out of 60 doses) (24)

**Data Collection Tools and Procedures**

Data extraction tool was developed from HIV/AIDS care monitoring and evaluation tools. The tool contains socio-demographic, baseline clinical and treatment related variables. Since it was based on secondary data, forms used for laboratory request, ART intake forms and patient charts were reviewed. Training was given for data collectors regarding each description of the tool and the way they collect data from patient chart using the extraction tool. Data were collected by three nurses who had experience on HIV care. A medical record
number of patients on the study period were taken from computer records in order to pick charts from patient chart room. Then data was collected from the patient’s medical charts by using prepared extraction tool. In order to avoid unintentional recollection of data, a commonly agreed code by data collectors was used. By this way all selected patient charts which fulfill the inclusion criteria were reviewed and data extraction was completed.

Data quality control

To maintain data quality, data extraction tool was pre-tested for consistency and completeness of data items on 5% of patient charts. Quality was also maintained by using experienced nurses on ART clinic. Even, training was given for data collectors before the data collection on the objective of the study and how to extract data for this study purpose using the data extraction format. Each component of the tool was discussed clearly for data collectors. Up on this, the data extraction process was monitored closely by the supervisor throughout the data collection period. Data clerk was also assist data collectors by identifying the charts. After filling each extraction tool, completeness was checked and correction was made before the chart was returned back.

Data processing and analysis

After the data was checked for its consistency and completeness, it was coded and entered to EPI-INFO version 7.2.2.6 and exported to STATA version 14.0 for analysis. Statistical summary was applied to describe socio demographic, clinical and follow up variables of the study. TB Incidence rate for the study period was calculated and described by using frequency tables. The rate was calculated by dividing number of new TB cases occurring during the follow up period to total follow up time in year and expressed as per 100 person year. To estimate TB free survival probability, Kaplan Meier was used. Log rank test was also used to test equality of survivor. Model fitness was checked by using schoenfield residual test (p-value = 0.419) and goodness of fit was checked by using Cox-Snell residual test. After applying bivariable analysis, those variables with p-value < 0.2 was entered to multivariable Cox-proportional hazard model to identify predictors of TB incidence rate. 95 % CI of hazard ratio was computed and variables having p value <0.05 in the multivariate Cox proportional hazards model was considered as significantly and independently associated with incident tuberculosis.

Ethical consideration

Ethical clearance was obtained from the Institutional Review Board (IRB) of the University of Gondar (Ref. No.:S/N/1600/06/2011). Letter of cooperation was gained from school of nursing to collect data. To retrieve the data from the patients’ record permission was obtained from Debre Markos Hospital Medical director and ART focal person. To ensure confidentiality, personal identifiers like name were not registered in the extraction tool.

Results

Baseline socio demographic characteristics of study participants
Out of all patients enrolled to the ART clinic from January 1, 2014 to December 31, 2018, a total of 536 charts were selected and reviewed based on the inclusion criteria. From those reviewed charts, 494 were included in the analysis and the remaining 42 (7.84%) charts were excluded due to data incompleteness.

From 494 charts included in the analysis, around 303 (61.3%) were females and about 200 (40.5%) from the total subjects were in the age group of 25 to 34 years. The median age for this cohort was 33 years (IQR: 27 – 40 years). Almost all of the patients 472 (95.6%) were orthodox Christian and 171 (34.6%) of the total patients had no formal education. More than three forth 377 (76.3%) were urban dwellers and 228 (46.2%) of the participants were living with the family number of 3 - 4 members. A total of 457 (92.5%) patients had disclosed their HIV status. Of these 228 (46.15%) disclosed their status to their wife or husband.

**Incidence of Tuberculosis**

All study participants were followed for different follow up periods for five years which gave a total of 1000.22 person year observations. Study subjects were followed for a minimum of 0.93 month and a maximum of 59.43 months. The median follow up period was 21.77 months (IQR: 7.27 – 37.7). During the total follow up period, 62 new TB case were observed which yielded a proportion of 12.55% (95% CI: 9.89, 15.79) and an overall incidence density rate of 6.19 cases per 100 person year (95% CI: 4.83, 7.95).

Among the incident TB cases diagnosed within the five years follow up period, 29 were males and 33 were females. From all new TB cases during the follow up, 25 subjects (40.3%) were within the age group of 35–44 years. Twenty four (38.7%) of new TB cases had no any formal education and most (82.3%) of TB cases were from a family size of three or more individuals (Table 1).

**Baseline and follow up clinical and immunological characteristics of study participants**

Out of the total 494 study participants with complete information for analysis, majority (97.17%) of them had not TB treatment history. A total of 219 (44.3%) patients were in baseline WHO clinical stages I. Only 38 (7.7%) of all patients had baseline CD4 count of less than 50 and majority were found in a group with CD4 count ≥ 350 cells/µl. The median base line CD4 count was 314.5 cells/µl (IQR: 147 - 443). Three hundred fifty nine patients (72.7%) were in the baseline hemoglobin level of ≥ 10 g/dl and the median hemoglobin level was 13.2 g/dl (IQR: 11.3 – 14.5).

Almost two third (67.4%) of participants were having a baseline body mass index of ≥ 18.5 kg/m² with median BMI of 20.58 kg/m² (IQR: 18.29 – 23.01). A total of 392 (79.4%) patients were enrolled to chronic HIV care clinic with working functional status. Only 79 (16%) patients had past opportunistic infections and from these only 13 patients (2.6%) had history of TB. Majority of patients, 467 (94.5%) were on TDF-3TC–EFV ART regimen at the baseline and only 16 (3.2%) of the participants were changed their regimen during follow up. Of those who have changed their initial regimen during follow up more than half (56.3%) were due to treatment failure. From all patients, 127 (25.7%) had fair or poor ART adherence level during follow up and 299 patients (60.5%) did not take IPT. More than one third (36.4%) of patients were followed for about 1 – 3 years.
From sixty two incident TB cases, TB were observed higher on patients with base line WHO clinical stage III (14.06 cases per 100 PY; 95% CI: 10.18, 19.40) and stage IV (26.37 cases per 100 PY; 95% CI: 14.97, 46.43). It was also observed that, TB incidence was noticeable among patients with baseline CD4 count of < 50 cells/µl (18.77 cases per 100 PY; 95% CI: 11.31, 31.13) and being from 50 – 100 cells/µl (18.93 cases per 100 PY; 95% CI: 11.93, 30.04). Patients with baseline hemoglobin < 10 g/dl was higher incidence, 20.17 cases per 100 PY (95% CI: 15.37 - 26.47). Of new TB cases, three fourth of cases had a BMI < 18.5 kg/m² having an incidence 16.32 cases per 100 PY (95% CI: 12.26 - 21.72).

Forty seven patients having baseline ambulatory or bedridden functional status developed TB during follow up with an incidence of 28.00 cases per 100 PY (95% CI: 21.04, 37.27). From those new TB patients during the follow up, 47 cases were fair or poor ART adherence contributed for an incidence rate of 19.89 cases per 100 PY (95% CI: 14.95, 26.48). An incidence of 9.61 cases per 100 PY (95% CI: 7.41, 12.45) was observed on those patients who did not take IPT during follow up period. The highest incidence of TB was seen within the first year of follow up (58.13 cases per 100 PY; 95% CI: 43.11 - 78.37) (Table 2).

**Kaplan-Meier plot for TB-free survival probability among adults on ART**

TB-free survival probability for the total cohort at the end of six month was 0.93 (95%CI; 0.90, 0.95); at the end of twelve month was 0.90 (95%CI; 0.87, 0.93); at the end of Two years was 0.88 (95%CI; 0.85, 0.91); at the end of three year was 0.86 (95%CI; 0.82, 0.89); at the end of four year was 0.83 (95%CI; 0.78, 0.88); and that of surviving TB free at the end of follow up was 0.66 (95%CI; 0.41, 0.83) (Figure 1).

Log rank test of equality of survival for baseline Hemoglobin level, Functional status, ART adherence level and IPT usage were significantly associated with TB incidence rate of people living with HIV. Patients whose baseline hemoglobin level less than 10g/dl had a significantly lower TB-free survival probability compared to those with hemoglobin ≥ 10g/dl. Those patients who had baseline functional status of working, used IPT during follow up and had good ART adherence had significantly higher TB free survival probability than those patients with ambulatory or bedridden functional status, didn't use IPT and had fair or poor ART adherence level respectively (Figure 2).

**Predictors of Tuberculosis occurrence**

In the bivariable Cox regression analysis, past TB treatment history, baseline CD4 count, WHO clinical stage at baseline, baseline haemoglobin level, baseline BMI, functional status at baseline, HIV disclosure status, ART adherence during follow up, and IPT use were found to be predictors of the incidence of TB among PLHIV at a P-value of less than 0.2. These variables were also checked for Cox proportional hazard assumption and they didn’t violate the assumption. So, they were selected for multivariable Cox-regression analysis. From these, baseline haemoglobin level, functional status at enrolment, IPT use and ART adherence level were found to be statistically significant predictors of TB incidence rate among adults on ART at a P-value of less than 0.05 (Table 3).

**Discussion**
Diagnosis of HIV-associated TB infection in the era of HAART has always been a difficult task and remains the major public health problems in many parts of the world. In this study, the overall incidence rate of TB among adults on ART is 6.19 cases per 100 PY (95% CI: 4.83 – 7.95). This finding is in line with TB incidence rate reported from Arbaminich general hospital which was 5.36 cases per 100 PY and university of Gondar referral hospital which was 7.88 cases per 100 PY. This similarity with the current study could be due to comparable sample size, equal length of follow up duration (i.e. five years); even the study settings were almost similar regarded to facilities and service provision (16, 18).

Lower TB incidence rate was observed in the current study than that of Afar public health facilities which was 8.6 cases per 100 PY (17). This might be that, in the current study, TB/HIV treatment guidelines were changing; hence, many patients have initiated ART earlier which justifies treatment as prevention (9). Improvement in TB/HIV care service integration, better awareness of the population regarding TB/HIV co-infection prevention might also contribute for the decrement(25, 26). Moreover, an increase in global and national concern towards TB/HIV co-infection than the previous years and difference in the socio economic status between Afar and Debre markos might contribute for the observed difference in TB incidence.

In contrary, TB incidence rate in the current study was higher than that of Zewditu memorial hospital (3.1 cases per 100 PY), Addis Ababa, Ethiopia. Zewdu hospital is the first public hospital in Ethiopia that begins to give HIV care services for patients and it is known by the quality of care delivered for PLHIV. So, this might contribute for the lower incidence of tuberculosis (15).

In the current study, the highest incidence rate of TB was observed in the first year of enrolment which was 58.13 cases per 100 PY (95% CI: 43.11, 78.37). This indicates that the highest probability of developing TB case after starting HAART was observed sooner. This study was also congruent with other studies conducted at Afar public health facilities (17) and University of Gondar referral hospital (18). This peak TB incidence shortly after enrollment might be due to ART induced unmasking of latent TB phase or new infection. Missing ART dose due to ART drug side effect nearly after enrolment might also contribute the high TB incidence at the first year of follow up (27).

This study showed that patients whose baseline hemoglobin level less than 10 g/dl were 5.25 times (AHR = 5.25; 95% CI: 2.52 – 10.95) at higher risk of developing TB at any time as compared to patients with hemoglobin level of greater than or equal to 10 g/dl. This is in line with previous studies conducted at Arbaminchi general hospital (16) and Addis Ababa (28). This might be due to the direct effect of HIV and its viral proteins on bone marrow stem cell results in bone marrow suppression which might cause anemia and the probability of predicting the occurrence of TB becomes high (29). This shows the need for earlier initiation of treatment to control and reduce virus number and prevent opportunistic infections by boosting immunity.

Patients with baseline ambulatory or bedridden functional status were 2.31 times at risk of developing TB as compared to patients with working functional status at enrolment to ART (AHR = 2.31; 95% CI: 1.13 – 4.73). This finding is agreed with other studies conducted in Afar public health facilities (AHR = 2.42), University of Gondar Hospital (AHR = 1.64) and Amhara regional state (AOR = 1.73) (17, 18, 30). This is due to the fact
that ambulatory or bedridden functional status is an indicator of low immune status and the presence of associated opportunistic infections, including TB (31).

Individuals who took IPT during follow up were 67% less likely to develop TB at any time as compared with those who did not take IPT (AHR = 0.33; 95% CI: 0.12 - 0.85). This might be due to the synergist role of IPT and ART drug in reducing the incidence of TB among PLHIV. Introduction of IPT to those patients on ART reduces the mycobacterium load which intern reduces the progression of latent TB to active one (32-34). This finding is consistent with those studies in Ethiopia (17, 28, 35, 36). This entails the need for provision of IPT for all eligible patients on HAART to prevent TB.

Level of adherence to HAART is also the predictors of incident TB to occur. Patients with fair or poor ART drug adherence were 3.22 times at risk of developing TB than patients with good ART drug adherence (AHR = 3.22; 95% CI: 1.64 - 6.31). This study was in line with a previous study conducted in Harari, Eastern Ethiopia (37). This might be due to the fact that, missing of ART dose might hinder the effect of ART drug on viral load suppression which in turn results in waning of CD4 cell count. Therefore, the patient became more susceptible to different opportunistic infection including TB.

Due to its retrospective nature and using of secondary data, this study was liable for incomplete data. Due to this few patient record with incomplete data were excluded from the analysis which might underestimate the result if it was related to TB. In addition, some important variables like viral load, monthly income and status of substance use were not included in this study due to un-recording habit.

**Conclusion**

Incidence of tuberculosis was high among adults on ART especially in the first year of enrollment to HAART. Low hemoglobin level, baseline ambulatory/bedridden functional status, ART adherence level and IPT usage status were found to be independent predictors of tuberculosis occurrence among adults on ART. Hence, tuberculosis prevention strategies among PLHIV need to be strengthened by ensuring optimum provision of Isoniazide (INH). Close follow up and screening of patients for tuberculosis is important especially with in the first year of enrollment to the chronic HIV care. It is better to give special attention for those patients with low level of hemoglobin at baseline and better to manage promptly. Continuous follow up regarding ART drug adherence is better and resolve a problem early, if any. It is better if Health workers give IPT for every patient eligible to the drug. If possible it is better to do prospective cohort study to incorporate all necessary variables which could be difficult to extract retrospectively. The impact of viral load on tuberculosis occurrence is better to be studied, which was not included in this study due to incomplete baseline data.

**List Of Abbreviations**
| Abbreviation | Full Form |
|--------------|-----------|
| 3TC          | Lamivudine|
| AFB          | Acid Fast Bacilli|
| AHR          | Adjusted Hazard Ratio|
| AIDS         | Acquired Immunodeficiency Syndrome|
| ART          | Antiretroviral Therapy|
| AZT          | Zidovudine|
| BMI          | Body Mass Index|
| CD4          | Cluster of Differentiation Four|
| CHR          | Crude Hazard Ratio|
| CI           | Confidence Interval|
| COR          | Crude Odds Ratio|
| CPT          | Cotrimoxazole Prophylactic Therapy|
| CSA          | Central Statistical Agency|
| HAART        | Highly Active Antiretroviral Therapy|
| Hgb          | Hemoglobin|
| HIV          | Human Immunodeficiency Virus|
| IDR          | Incidence Density Rate|
| INH          | Isoniazid|
| IPT          | Isoniazid Preventive Therapy|
| MDR          | Multi Drug Resistant|
| NVP          | Nevirapine|
| OIs          | Opportunistic Infections|
| PLHIV        | People Living With Human Immunodeficiency Virus|
| PY           | Person-year|
| SDGs         | Sustainable Development Goals|
| TB           | Tuberculosis|
| TDF          | Tenofovir Disoproxil Fumarate|
| UNAIDS       | The Joint United Nations Program on HIV/AIDS|
| WHO          | World Health Organization|
Declarations

Ethics approval and consent to participate

Ethical clearance was obtained from the Institutional Review Board (IRB) of the University of Gondar (Ref. No.: S/N/1600/06/2011). Letter of cooperation was gained from school of nursing to collect data. To retrieve the data from the patients’ record permission was obtained from Debre Markos Hospital Medical director and ART focal person. To ensure confidentiality, personal identifiers like name were not registered in the extraction tool.

Consent to publication

Not applicable

Availability of Data and Materials

All relevant data are available within the manuscript

Competing Interests

The authors have declared that they have no competing interests.

Funding: The authors received no specific funding for this work.

Authors’ contributions

AA conceived the idea and wrote the proposal, participated in the data collection process, analyze data and draft the manuscript. AJ and DZ approved the proposal with some revisions, participated in data analysis and reviewed the manuscript. All authors approved the final draft of the manuscript.

Acknowledgments

The authors would like to thank the data collectors for their collaboration during the data collection. We would also like to thank University of Gondar for providing ethical clearance.

References

1. JointUnitedNationsProgrammeonHIV/AIDS. Global HIV statistics. Fact sheet. 2017.
2. Blanc F-X, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. New England Journal of Medicine. 2011;365(16):1471-81.
3. Glaziou P, Floyd K, Raviglione MC, editors. Global Epidemiology of Tuberculosis. Seminars in respiratory and critical care medicine; 2018: Thieme Medical Publishers.
4. Khazaei S, Molaeipoor L, Rezaeian S, Ayubi E, Yari M, Valipour AA. Predictors of tuberculosis in hiv/aids patients referred to behavioral diseases consultation center: A registry-based study in Abadan,
5. Organization WH. Frequently asked questions about TB and HIV. www who int/tb/hiv/faq. 2011.

6. Sulis G, Roggi A, Matteelli A, Raviglione MC. Tuberculosis: epidemiology and control. Mediterranean journal of hematology and infectious diseases. 2014;6(1).

7. Organization WH. HIV-Associated Tuberculosis 2018 october.

8. Health FDROEMO. National comprehensive tuberculosis, leprosy and TB/HIV training manual for health care workers. 2016 [Accessed from: file:///C:/Users/Computer/Downloads/ethiopiannewtbguidlinenovember2016-170604054049.pdf ] [Last accessed: 20/01/2019].

9. Suthar AB, Lawn SD, Del Amo J, Getahun H, Dye C, Sculier D, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS medicine. 2012;9(7):e1001270.

10. Getahun H, Gunneberg C, Granich R, Nunn P. HIV infection—associated tuberculosis: the epidemiology and the response. Clinical Infectious Diseases. 2010;50(Supplement_3):S201-S7.

11. Lawn SD, Wood R. Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis. Journal of Infectious Diseases. 2011;204(suppl_4):S1159-S67.

12. Vision W. Technical Guideline for Tuberculosis and TB-HIV Program Implementation. 2017

13. Organization WH. Global tuberculosis report 2018: World Health Organization; 2018.

14. Deribew A, Tesfaye M, Hailmichael Y, Negussu N, Daba S, Wogi A, et al. Tuberculosis and HIV co-infection: its impact on quality of life. Health and quality of life outcomes. 2009;7(1):105.

15. Kassa A, Teka A, Shewaamare A, Jerene D. Incidence of tuberculosis and early mortality in a large cohort of HIV infected patients receiving antiretroviral therapy in a tertiary hospital in Addis Ababa, Ethiopia. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2012;106(6):363-70.

16. Dalbo M, Tamiso A. Incidence and Predictors of Tuberculosis among HIV/AIDS Infected Patients: a five-year retrospective follow-up study. Advances in Infectious Diseases. 2016;6(02):70.

17. Ahmed A, Mekonnen D, Kindie M. Incidence and Predictors of Tuberculosis among Adult People Living with HIV/AIDS in Afar Public Health Facilities, Northeast Ethiopia. AIDS. 2015;1:3-10.

18. Alene KA, Nega A, Taye BW. Incidence and predictors of tuberculosis among adult people living with human immunodeficiency virus at the University of Gondar Referral Hospital, Northwest Ethiopia. BMC infectious diseases. 2013;13(1):292.

19. Wikipedia. Debre Marqos: Cited from:https://en.wikipedia.org/wiki/Debre_Marqos.

20. Moges N, Kassa G. Prevalence of opportunistic infections and associated factors among HIV positive patients taking anti-retroviral therapy in DebreMarkos Referral Hospital, Northwest Ethiopia. J AIDS Clin Res. 2014;5(5):1-300.

21. Teshager FA, Engeda EH, Worku WZ. Knowledge, practice, and associated factors towards prevention of surgical site infection among nurses working in Amhara regional state referral hospitals, Northwest Ethiopia. Surgery research and practice. 2015;2015.
22. Mossie TB, Tegegne MT. HIV dementia among HIV positive people at Debre markos hospital, Northwest Ethiopia. Am J Psychol Neurosci. 2014;2:18-24.

23. Health Mo. National guidelines for comprehensive HIV prevention, care and treatment. 2017 [Accessed from https://aidsfree.usaid.gov/sites/default/files/resources/ethiopia_art_guidelines_2017.pdf] (Last accessed date: 22/01/2019).

24. Ministry of Health E. National Comprehensive HIV Prevention, Care and Treatment Training for Health care Providers: Participant Manual. 2017

25. CDC. Ethiopia - CDC Division of Global HIV & TB - Country Profile. 2019.

26. Yassin MA, Datiko DG, Tulloch O, Markos P, Aschalew M, Shargie EB, et al. Innovative community-based approaches doubled tuberculosis case notification and improve treatment outcome in Southern Ethiopia. PloS one. 2013;8(5):e63174.

27. Sharma SK, Soneja M. HIV & immune reconstitution inflammatory syndrome (IRIS). The Indian journal of medical research. 2011;134(6):866.

28. Kibret KT, Yalew AW, Belaineh BG, Asres MM. Determinant factors associated with occurrence of tuberculosis among adult people living with HIV after antiretroviral treatment initiation in Addis Ababa, Ethiopia: a case control study. PLoS One. 2013;8(5):e64488.

29. Assefa M, Abegaz WE, Shewamare A, Medhin G, Belay M. Prevalence and correlates of anemia among HIV infected patients on highly active anti-retroviral therapy at Zewditu Memorial Hospital, Ethiopia. BMC hematology. 2015;15(1):6.

30. Mitku AA, Dessie ZG, Muluneh EK, Workie DL. Prevalence and associated factors of TB/HIV co-infection among HIV Infected patients in Amhara region, Ethiopia. African health sciences. 2016;16(2):588-95.

31. Thejus T, Jeeja M, Jayakrishnan T. The functional status of patients with AIDS attending antiretroviral treatment center. Indian Journal of palliative care. 2009;15(1):57.

32. Rangaka MX, Wilkinson RJ, Boulle A, Glynn JR, Fielding K, Van Cutsem G, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. The Lancet. 2014;384(9944):682-90.

33. Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, Shang N, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. The Lancet. 2011;377(9777):1588-98.

34. Assebe LF, Reda HL, Wubeneh AD, Lerebo WT, Lambert SM. The effect of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: a retrospective cohort study. BMC Public Health. 2015;15(1):346.

35. Yirdaw KD, Jerene D, Gashu Z, Edginton M, Kumar AM, Letamo Y, et al. Benecial effect of isoniazid preventive therapy and antiretroviral therapy on the incidence of tuberculosis in people living with HIV in Ethiopia. PloS one. 2014;9(8):e104557.

36. Alemu YM, Awoke W, Wilder-Smith A. Determinants for tuberculosis in HIV-infected adults in Northwest Ethiopia: a multicentre case–control study. BMJ open. 2016;6(4):e009058.

37. Geleto A, Abate D, Egata G. Intensified tuberculosis case finding, implementation of isoniazid preventive therapy and associated factors among people living with human immunodeficiency virus at public
Tables

Table 1: Socio-demographic characteristics and Tuberculosis incidence density rate stratified by socio-demographic characteristics of adults on ART at Debre-Markos Referral Hospital from January 1, 2014 to December 31, 2018 (n = 494).
| Characteristics          | Frequency (n= 494) | Percent (%) | Person year | TB (n=62) | Censored (n=432) | TB IDR per 100 PY (95% CI) |
|--------------------------|--------------------|-------------|-------------|-----------|-----------------|---------------------------|
| **Age (years)**          |                    |             |             |           |                 |                           |
| 15 - 24                  | 61                 | 12.35       | 120.43      | 6         | 55              | 4.99 (2.24, 11.09)        |
| 25 - 34                  | 200                | 40.49       | 418.92      | 21        | 179             | 5.01 (3.27, 7.69)         |
| 35 - 44                  | 160                | 32.39       | 314.16      | 25        | 135             | 7.96 (5.38, 11.78)        |
| ≥ 45                     | 73                 | 14.78       | 146.72      | 10        | 63              | 6.82 (3.67, 12.67)        |
| **Sex of patient**       |                    |             |             |           |                 |                           |
| Male                     | 191                | 38.66       | 362.88      | 29        | 162             | 7.99 (5.55, 11.50)        |
| Female                   | 303                | 61.34       | 637.35      | 33        | 270             | 5.18 (3.68, 7.28)         |
| **Marital status**       |                    |             |             |           |                 |                           |
| Single                   | 62                 | 12.55       | 95.32       | 11        | 51              | 11.54 (6.39, 20.84)       |
| Married                  | 267                | 54.05       | 572.27      | 33        | 234             | 5.77 (4.09, 8.11)         |
| Divorced/separated       | 129                | 26.11       | 271.63      | 12        | 117             | 4.42 (2.51, 7.78)         |
| Widowed                  | 36                 | 7.29        | 61.01       | 6         | 30              | 9.83 (4.42, 21.89)        |
| **Educational status**   |                    |             |             |           |                 |                           |
| No education             | 171                | 34.60       | 357.45      | 24        | 147             | 6.71 (4.50, 10.02)        |
| Primary                  | 113                | 22.90       | 215.81      | 19        | 94              | 8.80 (5.62, 13.80)        |
| Secondary & above        | 210                | 42.51       | 426.96      | 19        | 191             | 4.45 (2.84, 6.98)         |
| **Occupation**           |                    |             |             |           |                 |                           |
| Has job                  | 159                | 32.19       | 250.92      | 16        | 143             | 6.38 (3.91, 10.41)        |
| Jobless                  | 109                | 22.06       | 201.25      | 19        | 90              | 9.44 (6.02, 14.80)        |
| Not recorded             | 226                | 45.75       | 548.05      | 27        | 199             | 4.93 (3.38, 7.18)         |
| **Residence**            |                    |             |             |           |                 |                           |
| Urban                    | 377                | 76.32       | 777.71      | 45        | 332             | 5.79 (4.32, 7.75)         |
| Rural                    | 117                | 23.68       | 222.51      | 17        | 100             | 7.64 (4.75, 12.29)        |
| **Family size**          |                    |             |             |           |                 |                           |
| ≤ 2                      | 197                | 39.88       | 372.33      | 11        | 186             | 2.95 (1.64, 5.33)         |
| 3 - 4                    | 228                | 46.15       | 475.49      | 43        | 185             | 9.04 (6.71, 12.19)        |
| ≥ 5                      | 69                 | 13.97       | 152.39      | 8         | 61              | 5.25 (2.63, 10.49)        |
| **HIV Disclosure Status**|                    |             |             |           |                 |                           |
| Disclosed                | 457                | 92.51       | 927.87      | 55        | 402             | 5.93 (4.55, 7.72)         |
| Not Disclosed            | 37                 | 7.49        | 72.35       | 7         | 30              | 9.68 (4.61, 20.29)        |
| **Total**                | 494                | 100         | 1000.22     | 62        | 432             | 6.19 (4.83, 7.95)         |
Table 2: Tuberculosis incidence density stratified by clinical and immunological characteristics of PLHIV on chronic HIV care at Debre-Markos Referral Hospital from January 1, 2014 to December 31, 2018 (N = 494).
| Characteristics                              | Frequency (n = 494) | Percent (%) | Person year | TB (n = 62) | Censored (n=432) | TB IR per 100 PY (95% CI) |
|---------------------------------------------|---------------------|-------------|-------------|-------------|------------------|----------------------------|
| Past TB treatment                           |                     |             |             |             |                  |                            |
| Yes                                         | 14                  | 2.83        | 36.14       | 6           | 8                | 16.60 (7.46, 36.95)        |
| No                                          | 480                 | 97.17       | 964.08      | 56          | 424              | 5.81 (4.47, 7.55)          |
| Baseline WHO clinical staging               |                     |             |             |             |                  |                            |
| Stage I                                     | 219                 | 44.33       | 396.81      | 7           | 212              | 1.77 (0.84, 3.70)          |
| Stage II                                    | 124                 | 25.10       | 294.67      | 6           | 118              | 2.04 (0.91, 4.53)          |
| Stage III                                   | 122                 | 24.70       | 263.23      | 37          | 85               | 14.06 (10.18, 19.40)       |
| Stage IV                                    | 29                  | 5.87        | 45.51       | 12          | 17               | 26.37 (14.97, 46.43)       |
| Baseline CD4 count (cells/µl)               |                     |             |             |             |                  |                            |
| < 50                                        | 38                  | 7.69        | 79.93       | 15          | 23               | 18.77 (11.31, 31.13)       |
| 50 - <100                                   | 51                  | 10.32       | 95.09       | 18          | 33               | 18.93 (11.93, 30.04)       |
| 100 - 200                                   | 75                  | 15.18       | 170.31      | 14          | 61               | 8.22 (4.87, 13.88)         |
| 201 - 350                                   | 123                 | 24.90       | 268.43      | 10          | 113              | 3.73 (2.00, 6.92)          |
| ≥ 350                                       | 207                 | 41.90       | 386.46      | 5           | 202              | 1.29 (0.54, 3.11)          |
| Baseline hemoglobin level (g/dl)            |                     |             |             |             |                  |                            |
| < 10                                        | 135                 | 27.33       | 257.82      | 52          | 83               | 20.17 (15.37, 26.47)       |
| ≥ 10                                        | 359                 | 72.67       | 742.41      | 10          | 349              | 1.35 (0.72, 2.50)          |
| Baseline body mass index (kg/m²)            |                     |             |             |             |                  |                            |
| < 18.5                                      | 161                 | 32.59       | 288.03      | 47          | 114              | 16.32 (12.26, 21.72)       |
| ≥ 18.5                                      | 333                 | 67.41       | 712.19      | 15          | 318              | 2.11 (1.27, 3.49)          |
| Baseline functional status                  |                     |             |             |             |                  |                            |
| Working                                     | 392                 | 79.35       | 832.36      | 15          | 377              | 1.80 (1.09, 2.99)          |
| Ambulate/bedridden                          | 102                 | 20.65       | 167.86      | 47          | 55               | 28.00 (21.04, 37.27)       |
| Past opportunistic infection (OIs)          |                     |             |             |             |                  |                            |
| Yes                                         | 79                  | 15.99       | 215.17      | 18          | 61               | 8.37 (5.27,13.28)          |
| No                                          | 415                 | 84.01       | 785.05      | 44          | 371              | 5.60 (4.17, 7.53)          |
| ART adherence                               |                     |             |             |             |                  |                            |
| Good                                        | 367                 | 74.29       | 763.97      | 15          | 352              | 1.96 (1.18, 3.25)          |
| Fair/poor                                   | 127                 | 25.71       | 236.25      | 47          | 80               | 19.89 (14.95, 26.48)       |
| Took IPT during follow up                   |                     |             |             |             |                  |                            |
| Yes                                         | 195                 | 39.47       | 406.90      | 5           | 190              | 1.23 (0.51, 2.95)          |
| No                                          | 299                 | 60.53       | 593.32      | 57          | 242              | 9.61 (7.41, 12.45)         |
| Total year of follow up                     |                     |             |             |             |                  |                            |
| ≤ 1 year                                    | 169                 | 34.21       | 73.98       | 43          | 126              | 58.13 (43.11, 78.37)       |
| >1 - < 3 years                               | 180                 | 36.44       | 353.47      | 11          | 169              | 3.11 (1.72, 5.53)          |
Table 3: Cox regression analysis of predictors of tuberculosis among cohorts of PLHIV on chronic HIV care at Debre-Markos Referral Hospital from January 1, 2014 to December 31, 2018 (n = 494).

| Variable                | Survival status | CHR (95% CI)          | Adjusted AHR (95% CI) | P-value |
|-------------------------|-----------------|-----------------------|-----------------------|---------|
|                         | Event | Censored |                         |         |
| **TB treatment**        |       |          |                         |         |
| Yes                     | 6     | 8        | 2.84 (1.22, 6.64)       | 1.01    | (0.38, 0.981) |
| No                      | 56    | 424      | 1.00                    | 1.00    |         |
| **V disclosure**        |       |          |                         |         |
| Disclosed               | 7     | 30       | 0.59 (0.27, 1.30)       | 0.74    | (0.31, 0.495) |
| Not disclosed           | 55    | 402      | 1.00                    | 1.00    |         |
| **HO staging**          |       |          |                         |         |
| I/II                    | 13    | 330      | 1.00                    | 1.00    |         |
| III                     | 37    | 85       | 7.55 (4.01, 14.22)      | 1.27    | (0.59, 0.534) |
| IV                      | 12    | 17       | 13.37 (6.09, 29.36)     | 2.18    | (0.86, 0.100) |
| **D4 count (cells/µl)**|       |          |                         |         |
| ≤ 200                   | 47    | 117      | 11.28 (4.48, 26.36)     | 2.31    | (0.85, 0.101) |
| 201 - 350               | 10    | 113      | 3.04 (1.04, 8.89)       | 1.34    | (0.43, 0.608) |
| ≥ 350                   | 5     | 202      | 1.00                    | 1.00    |         |
| **Hb level**            |       |          |                         |         |
| < 10 g/dl               | 52    | 83       | 14.41 (7.32, 28.38)     | 5.25    | (2.52, 10.95) |
| ≥ 10 g/dl               | 10    | 349      | 1.00                    | 1.00    |         |
| **MI (kg/m²)**          |       |          |                         |         |
| < 18.5                  | 47    | 114      | 7.51 (4.19, 13.44)      | 1.97    | (0.99, 0.052) |
| ≥ 18.5                  | 15    | 318      | 1.00                    | 1.00    |         |
| **Categorical status**  |       |          |                         |         |
| Working                 | 15    | 377      | 1.00                    | 1.00    |         |
| Ambulatory/bedridden    | 47    | 55       | 14.10 (7.87, 25.28)     | 2.31    | (1.13, 0.021) |
| **T adherence**          |       |          |                         |         |
| Good                    | 15    | 352      | 1.00                    | 1.00    |         |
| Fair /poor              | 47    | 80       | 9.76 (5.45, 17.47)      | 3.22    | (1.64, 0.001) |
| **IPT**                 |       |          |                         |         |
| Yes                     | 5     | 190      | 0.13 (0.05, 0.31)       | 0.33    | (0.12, 0.023) |
| No                      | 57    | 242      | 1.00                    | 1.00    |         |

* Independently significant predictors of TB at p-value < 0.05
Figure 1

Kaplan-Meier curve of TB-free survival probability among cohorts of PLHIV on chronic HIV care at Debre-Markos Referral Hospital from January 1, 2014 to December 31, 2018.
Figure 2
Kaplan-Meier plots of TB-free survival probability: (A) stratified by baseline Hgb level (B) by functional status; (C) by ART adherence; (D) by IPT use among PLHIV on chronic HIV care at Debre-Markos Referral Hospital: Jan 1, 2014 to December 31, 2018.